ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Winter Discusses Copanlisib in Follicular Lymphoma

Jane N. Winter, MD
Published: Friday, Nov 17, 2017



Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the PI3K-alpha and -delta isoforms in follicular lymphoma.

Winter says that the category of PI3K inhibitors continues to grow in this disease, and this class of agents will positively add to the armamentarium.
 


Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma.

The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the PI3K-alpha and -delta isoforms in follicular lymphoma.

Winter says that the category of PI3K inhibitors continues to grow in this disease, and this class of agents will positively add to the armamentarium.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x